Amalgamated Financial’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Amalgamated Financial’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$20K	Buy	+16	New	+$21.8K	﹤0.01%	2752

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Amalgamated Financial's IRLA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2022: 16 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #2752 among its holdings.

85 funds tracked by Wall St. Rank hold IRLA as of Q1 2022.

Amalgamated Financial held 16 shares of IRulya Therapeutics Inc. Common Stock worth $20K as of Q1 2022.
IRulya Therapeutics Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2752 holding.
85 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.